Barriers to successful transplantation of the sensitized patient

References

• Eng HS, Bennett G, Bardy P, Coghlan P, Russ GR, Coates TH. Clinical significance of anti-HLA antibodies detected by Luminex®: enhancing the interpretation of CDC-BXM and important post-transplantation monitoring tools. Hum. Immunol.70(8), 595–599 (2009).
   PubMedGoogle Scholar
• Lee PC, Ozawa M. Reappraisal of HLA antibody analysis and crossmatching in kidney transplantation. In: Clinical Transplants 2007. Cecka JM, Terasaki PI (Eds). Terasaki Foundation Laboratory, CA, USA, 219–226 (2008).
   Google Scholar
• Gibney EM, Cagle LR, Freed B, Warnell SE, Chan L, Wiseman AC. Detection of donor-specific antibodies using HLA-coated microspheres: another tool for kidney transplant risk stratification. Nephrol. Dial. Transplant.21(9), 2625–2629 (2006).
   PubMed Web of Science ®Google Scholar
• Zachary AA, Montgomery RA, Leffell MS. Factors associated with and predictive of persistence of donor-specific antibody after treatment with plasmapheresis and intravenous immunoglobulin. Hum. Immunol.66(4), 364–370 (2005).
   PubMed Web of Science ®Google Scholar
• Phelan D, Mohanakumar T, Ramachandran S, Jendrisak MD. Living donor renal transplantation in the presence of donor-specific human leukocyte antigen antibody detected by solid-phase assay. Hum. Immunol.70(8), 584–588 (2009).
   PubMedGoogle Scholar
• Zachary AA, Montgomery RA, Leffell MS. Defining unacceptable HLA antigens. Curr. Opin. Organ. Transplant.13(4), 405–410 (2008).
   PubMedGoogle Scholar
• Zachary AA, Braun WE. Calculation of a predictive value for transplantation. Transplantation39(3), 316–318 (1985).
   PubMedGoogle Scholar
• Zachary AA, Leffell MS. Detecting and monitoring human leukocyte antigen-specific antibodies. Hum. Immunol.69(10), 591–604 (2008).
   PubMedGoogle Scholar
• Zeevi A, Lunz JG III, Shapiro R et al. Emerging role of donor-specific anti-human leukocyte antigen antibody determination for clinical management after solid organ transplantation. Hum. Immunol.70(8), 645–650 (2009).
   PubMed Web of Science ®Google Scholar
• Samaniego M, Mezrich J, Torrealba J et al. C4d-positive acute antibody-mediated rejection due to anti-HLA-DP antibody: a tale of one patient and a review of the University of Wisconsin Experience. In: Clinical Transplants 2006. Terasaki PI (Ed.). Terasaki Foundation Laboratory, CA, USA, 503–507 (2007).
   Google Scholar
• Thaunat O, Hanf W, Dubois V et al. Chronic humoral rejection mediated by anti-HLA-DP alloantibodies: insights into the role of epitope sharing in donor-specific alloantibodies generation. Transpl. Immunol.20(4), 209–211 (2009).
   PubMed Web of Science ®Google Scholar
• Vaidya S, Hilson B, Sheldon S, Cano P, Fernandez-Vina M. DP reactive antibody in a zero mismatch renal transplant pair. Hum. Immunol.68(12), 947–949 (2007).
   PubMedGoogle Scholar
• Pfeiffer K, Vögeler U, Albrecht KH, Eigler FW, Buchholz B, Grosse-Wilde H. HLA-DP antibodies in patients awaiting renal transplantation. Transpl. Int.8(3), 180–184 (1995).
   PubMedGoogle Scholar
• Callender CJ, Chesterton KA, Kaplan I, Leffell MS, Zachary AA. Frequency of DP antibodies. Hum. Immunol.69(1 Suppl.), S11 (2008).
   Google Scholar
• Stastny P, Zou Y, Fan Y, Qin Z, Lavingia B. The emerging issue of MICA antibodies: antibodies to MICA and other antigens of endothelial cells. Contrib. Nephrol.162, 99–106 (2009).
   PubMedGoogle Scholar
• Mizutani K, Terasaki P, Bignon JD et al. Association of kidney transplant failure and antibodies against MICA. Hum. Immunol.67(9), 683–691 (2006).
   PubMedGoogle Scholar
• Sumitran-Holgersson S, Wilczek HE, Holgersson J, Söderström K. Identification of the nonclassical HLA molecules, MICA, as targets for humoral immunity associated with irreversible rejection of kidney allografts. Transplantation74(2), 268–277 (2002).
   PubMed Web of Science ®Google Scholar
• Zou Y, Stastny P, Süsal C, Döhler B, Opelz G. Antibodies against MICA antigens and kidney-transplant rejection. N. Engl. J. Med.357(13), 1293–1300 (2007).
   PubMed Web of Science ®Google Scholar
• Terasaki PI, Ozawa M, Castro R. Four year follow-up of a prospective trial of HLA and MICA antibodies on kidney graft survival. Am. J. Transplant.7(2), 408–415 (2007).
   PubMed Web of Science ®Google Scholar
• Zou Y, Heinemann FM, Grosse-Wilde H et al. Detection of anti-MICA antibodies in patients awaiting kidney transplantation, during the post-transplant course, and in eluates from rejected kidney allografts by Luminex flow cytometry. Hum. Immunol.67(3), 230–237 (2006).
   PubMedGoogle Scholar
• Stastny P, Zou Y, Fan Y, Qin Z, Lavingia B. The emerging issue of MICA antibodies: antibodies to MICA and other antigens of endothelial cells. Contrib. Nephrol.162, 99–106 (2009).
   PubMedGoogle Scholar
• Smith JD, Brunner VM, Jigidsuren S et al. Lack of effect of MICA antibodies on graft survival following heart transplantation. Am. J. Transplant.9(8), 1912–1919 (2009).
   PubMedGoogle Scholar
• Breimer ME, Rydberg L, Jackson AM et al. Multicenter evaluation of a novel endothelial cell crossmatch test in kidney transplantation. Transplantation87(4), 549–556 (2009).
   PubMed Web of Science ®Google Scholar
• Stastny P, Ring S, Lu C, Arenas J, Han M, Lavingia B. Role of immunoglobulin (Ig)-G and IgM antibodies against donor human leukocyte antigens in organ transplant recipients. Hum. Immunol.70(8), 600–604 (2009).
   PubMedGoogle Scholar
• Suzuki M, Ishida H, Komatsu T, Kennoki T, Ishizuka T, Tanabe K. Kidney transplantation in a recipient with anti-HLA antibody IgM positive. Transpl. Immunol.21(3), 150–154 (2009).
   PubMedGoogle Scholar
• Mai ML, Ahsan N, Wadei HM et al. Excellent renal allograft survival in donor-specific antibody positive transplant patients-role of intravenous immunoglobulin and rabbit antithymocyte globulin. Transplantation87(2), 227–232 (2009).
   PubMedGoogle Scholar
• O’Rourke RW, Osorio RW, Freise CE et al. Flow cytometry crossmatching as a predictor of acute rejection in sensitized recipients of cadaveric renal transplants. Clin. Transplant.14(2), 167–173 (2000).
   PubMedGoogle Scholar
• Wen R, Wu V, Dmitrienko S, Yu A, Balshaw R, Keown PA. Biomarkers in transplantation: prospective, blinded measurement of predictive value for the flow cytometry crossmatch after negative antiglobulin crossmatch in kidney transplantation. Kidney Int.70(8), 1474–1481 (2006).
   PubMedGoogle Scholar
• Süsal C, Döhler B, Sadeghi M, Ovens J, Opelz G. HLA antibodies and the occurrence of early adverse events in the modern era of transplantation: a Collaborative Transplant Study report. Transplantation87(9), 1367–1371 (2009).
   PubMed Web of Science ®Google Scholar
• Lefaucheur C, Suberbielle-Boissel C, Hill GS et al. Clinical relevance of preformed HLA donor-specific antibodies in kidney transplantation. Contrib. Nephrol.162, 1–12 (2009).
   PubMedGoogle Scholar
• Amico P, Hönger G, Mayr M, Steiger J, Hopfer H, Schaub S. Clinical relevance of pretransplant donor-specific HLA antibodies detected by single-antigen flow-beads. Transplantation87(11), 1681–1688 (2009).
   PubMed Web of Science ®Google Scholar
• Gupta A, Sinnott P. Clinical relevance of pretransplant human leukocyte antigen donor-specific antibodies in renal patients waiting for a transplant: a risk factor. Hum. Immunol.70(8), 618–622 (2009).
   PubMedGoogle Scholar
• Vlad G, Ho EK, Vasilescu E et al. Relevance of different antibody detection methods for the prediction of antibody-mediated rejection and deceased-donor kidney allograft survival. Hum. Immunol.70(8), 589–594 (2009).
   PubMed Web of Science ®Google Scholar
• Zachary AA, Montgomery RA, Jordan SC, Reinsmoen NL, Claas FHJ, Reed EF. 14th International HLA and Immunogenetics Workshop: report on understanding antibodies in transplantation. Tissue Antigens.69(1 Suppl.), 160–173 (2007).
   PubMedGoogle Scholar
• Montgomery RA, Zachary AA. Transplanting patients with a positive donor-specific crossmatch: a single center’s perspective. Pediatr. Transplant.8, 535–542 (2004).
   PubMed Web of Science ®Google Scholar
• Leffell M, Locke J, Houp J, Montgomery R, Zachary A. Successful transplantation of patients with low level donor HLA specific antibody without desensitization treatment. Transplantation86(2 Suppl.), 184 (2008).
   Google Scholar
• Jindra PT, Zhang X, Mulder A et al. Anti-HLA antibodies can induce endothelial cell survival or proliferation depending on their concentration. Transplantation82(1S), S33–S35 (2006).
   PubMed Web of Science ®Google Scholar
• Narayanan K, Jaramillo A, Phelan DL, Mohanakumar T. Pre-exposure to sub-saturating concentrations of HLA class I antibodies confers resistance to endothelial cells against antibody complement-mediated lysis by regulating Bad through the phosphatidylinositol 3-kinase/Akt pathway. Eur. J. Immunol.34(8), 2303–2312 (2004).
   PubMedGoogle Scholar
• Arnold ML, Dechant M, Doxiadis II, Spriewald BM. Prevalence and specificity of immunoglobulin G and immunoglobulin A non-complement-binding anti-HLA alloantibodies in retransplant candidates. Tissue Antigens72(1), 60–66 (2008).
   PubMedGoogle Scholar
• Rose ML, Smith JD. Clinical relevance of complement-fixing antibodies in cardiac transplantation. Hum. Immunol.70(8), 605–609 (2009).
   PubMedGoogle Scholar
• Zachary AA, Lucas DP, Detrick B, Leffell MS. Naturally occurring interference in Luminex® assays for HLA-specific antibodies: characteristics and resolution. Hum. Immunol.70(7), 496–501 (2009).
   PubMed Web of Science ®Google Scholar
• Warner P. Nebulous humors: defining alloantibodies in the 21st century. Hum. Immunol.70(8), 623–626 (2009).
   PubMedGoogle Scholar
• Fuggle SV, Martin S. Tools for human leukocyte antigen antibody detection and their application to transplanting sensitized patients. Transplantation86, 384–390 (2008).
   PubMed Web of Science ®Google Scholar
• Lachmann N, Terasaki P, Budde K et al. Anti-human leukocyte antigen and donor-specific antibodies detected by Luminex posttransplant serve as biomarkers for chronic rejection of renal allografts. Transplantation87(10), 1505–1513 (2009).
   PubMed Web of Science ®Google Scholar
• Zhang Q, Liang LW, Gjertson DW et al. Development of posttransplant antidonor HLA antibodies is associated with acute humoral rejection and early graft dysfunction. Transplantation79(5), 591–598 (2005).
   PubMedGoogle Scholar
• Mihaylova A, Baltadjieva D, Boneva P et al. Clinical relevance of anti-HLA antibodies detected by flow-cytometry bead-based assays-single-center experience. Hum. Immunol.67(10), 787–794 (2006).
   PubMedGoogle Scholar
• Ozawa M, Terasaki PI, Castro R et al. 14th International HLA and Immunogenetics Workshop Prospecitve Chronic Rejection Project: a three-year follow-up analysis. In: Clinical Transplants 2007. Cecka JM, Terasaki PI (Eds). Terasaki Foundation Laboratory, CA, USA, 255–260 (2008).
   Google Scholar
• Terasaki PI, Cai J. Human leukocyte antigen antibodies and chronic rejection: from association to causation. Transplantation86, 377–383 (2008).
   PubMed Web of Science ®Google Scholar
• Claas FH, Doxiadis II. Management of the highly sensitized patient. Curr. Opin. Immunol.21, 1–4 (2009).
   PubMedGoogle Scholar
• Claas FH, Witvliet MD, Duquesnoy RJ, Persijn GG, Doxiadis II. The acceptable mismatch program as a fast tool for highly sensitized patients awaiting a cadaveric kidney transplantation: short waiting time and excellent graft outcome. Transplantation78(2), 190–193 (2004).
   PubMed Web of Science ®Google Scholar
• Zachary AA, Kopchaliiska D, Montgomery RA, Leffell MS. HLA-specific B cells: II. Application to transplantation. Transplantation83, 989–994 (2006).
   Google Scholar
• Roodnat JI, Kal-van Gestel JA, Zuidema W et al. Successful expansion of the living donor pool by alternative living donation programs. Am. J. Transplant.9(9), 2150–2156 (2009).
   PubMedGoogle Scholar
• Ferrari P, Woodroffe C, Christiansen FT. Paired kidney donations to expand the living donor pool: the Western Australian experience. Med. J. Aust.190(12), 700–703 (2009).
   PubMedGoogle Scholar
• Hanto RL, Reitsma W, Delmonico FL. The development of a successful multiregional kidney paired donation program. Transplantation86(12), 1744–1748 (2008).
   PubMedGoogle Scholar
• Montgomery RA, Katznelson S, Bry WI et al. Successful three-way kidney paired donation with cross-country live donor allograft transport. Am. J. Transplant.8(10), 2163–2168 (2008).
   PubMed Web of Science ®Google Scholar
• Gentry SE, Segev DL, Simmerling M, Montgomery RA. Expanding kidney paired donation through participation by compatible pairs. Am. J. Transplant.7(10), 2361–2370 (2007).
   PubMed Web of Science ®Google Scholar
• Gentry SE, Montgomery RA, Swihart BJ, Segev DL. The roles of dominos and nonsimultaneous chains in kidney paired donation. Am. J. Transplant.9(6), 1330–1336 (2009).
   PubMedGoogle Scholar
• Rees MA, Kopke JE, Pelletier RP et al. A nonsimultaneous, extended, altruistic-donor chain. N. Engl. J. Med.360(11), 1096–1101 (2009).
   PubMed Web of Science ®Google Scholar
• Kaplan I, Houp JA, Montgomery RA, Leffell MS, Hart JM, Zachary AA. A computer program for paired and unconventional kidney exchange. Am. J. Transplant.5(9), 2306–2308 (2005).
   PubMedGoogle Scholar
• Bingaman AW, Murphey CL, Palma-Vargas J, Wright F. A virtual crossmatch protocol significantly increases access of highly sensitized patients to decreased donor kidney transplantation. Transplantation86(12), 1864–1868 (2008).
   PubMedGoogle Scholar
• Zachary AA, Sholander JT, Houp JA, Leffell MS. Using real data for a virtual crossmatch. Hum. Immunol.70(8), 574–578 (2009).
   PubMedGoogle Scholar
• Appel JZ 3rd, Hartwig MG, Cantu E 3rd, Palmer SM, Reinsmoen NL, David RD. Role of flow cytometry to define unacceptable HLA antigens in lung transplant recipients with HLA-specific antibodies. Transplantation81, 1049–1057 (2006).
   PubMedGoogle Scholar
• Jordan SC, Tyan D, Stablein D et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial. J. Am. Soc. Nephrol.15(12), 3256–3262 (2004).
   PubMed Web of Science ®Google Scholar
• Vo AA, Lukovsky M, Toyoda M et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N. Engl. J. Med.359(3), 242–251 (2008).
   PubMed Web of Science ®Google Scholar
• Zachary AA, Montgomery RA, Ratner LE et al. Specific and durable elimination of antibody to donor HLA antigen in renal transplant patients. Transplantation76(10), 1519–1525 (2003).
   PubMedGoogle Scholar
• Montgomery RA, Locke JE, King KE et al. ABO incompatible renal transplantation: a paradigm ready for broad implementation. Transplantation87(8), 1246–1255 (2009).
   PubMed Web of Science ®Google Scholar
• Fehr T, Rüsi B, Fischer A, Hopfer H, Wüthrich RP, Gaspert A. Rituximab and intravenous immunoglobulin treatment of chronic antibody-mediated kidney allograft rejection. Transplantation87(12), 1837–1841 (2009).
   PubMed Web of Science ®Google Scholar
• Billing H, Rieger S, Ovens J et al. Successful treatment of chronic antibody-mediated rejection with IVIG and rituximab in pediatric renal transplant recipients. Transplantation86(9), 1214–1221 (2008).
   PubMed Web of Science ®Google Scholar
• Jordan SC, Quartel AW, Czer LS et al. Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action. Transplantation66(6), 800–805 (1998).
   PubMed Web of Science ®Google Scholar
• Rocha PN, Butterly DW, Greenberg A et al. Beneficial effect of plasmapheresis and intravenous immunoglobulin on renal allograft survival of patients with acute humoral rejection. Transplantation75(9), 1490–1495 (2003).
   PubMed Web of Science ®Google Scholar
• Montgomery RA, Zachary AA, Racusen LC et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation70(6), 887–895 (2000).
   PubMed Web of Science ®Google Scholar
• Ibernón M, Gil-Vernet S, Carrera M et al. Therapy with plasmapheresis and intravenous immunoglobulin for acute humoral rejection in kidney transplantation. Transplant. Proc.37(9), 3743–3745 (2005).
   PubMed Web of Science ®Google Scholar
• Lehrich RW, Rocha PN, Reinsmoen N et al. Intravenous immunoglobulin and plasmapheresis in acute humoral rejection: experience in renal allograft transplantation. Human Immunol.66(4), 350–358 (2005).
   PubMed Web of Science ®Google Scholar
• Zarkhin V, Li L, Kambham N, Sigdel T, Salvatierra O, Sarwal MM. A randomized, prospective trial of rituximab for acute rejection in pediatric renal transplantation. Am. J. Transplant.8(12), 2607–2617 (2008).
   PubMed Web of Science ®Google Scholar
• Becker YT, Becker BN, Pirsch JD, Sollinger HW. Rituximab as treatment for refractory kidney transplant rejection. Am. J. Transplant.4(6), 996–1001 (2004).
   PubMed Web of Science ®Google Scholar
• Montgomery R, Simpkins C, Zachary A et al. Anti-CD20 rescue therapy for refractory kidney transplant rejection. Am. J. Transplant.4(Suppl. 8), 258 (2004).
   Google Scholar
• Mulley WR, Hudson FJ, Tait BD et al. A single low-fixed dose of rituximab to salvage renal transplants from refractory antibody-mediated rejection. Transplantation87(2), 286–289 (2009).
   PubMed Web of Science ®Google Scholar
• Locke JE, Magro CM, Singer AL et al. The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection. Am. J. Transplant.9(1), 231–235 (2009).
   PubMed Web of Science ®Google Scholar
• Kaplan B, Gangemi A, Thielke J, Oberholzer J, Sankary H, Benedetti E. Successful rescue of refractory, severe antibody mediated rejection with splenectomy. Transplantation83(1), 99–100 (2007).
   PubMed Web of Science ®Google Scholar
• Locke JE, Zachary AA, Haas M et al. The utility of splenectomy as rescue treatment for severe acute antibody mediated rejection. Am. J. Transplant.7(4), 842–846 (2007).
   PubMed Web of Science ®Google Scholar
• Perry DK, Burns JM, Pollinger HS et al. Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am. J. Transplant.9(1), 201–209 (2009).
   PubMed Web of Science ®Google Scholar
• Everly MJ, Everly JJ, Arend LJ et al. Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss. Am. J. Transplant.9(5), 1063–1071 (2009).
   PubMed Web of Science ®Google Scholar
• Everly MJ, Everly JJ, Susskind B et al. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation86(12), 1754–1761 (2008).
   PubMed Web of Science ®Google Scholar
• Everly MJ, Everly JJ, Susskind B et al. Proteasome inhibition reduces donor-specific antibody levels. Transplant. Proc.41(1), 105–107 (2009).
   PubMedGoogle Scholar
• Locke JE, Zachary AA, Warren DS et al. Proinflammatory events are associated with significant increases in breadth and strength of HLA-specific antibody. Am. J. Transplant.9, 2136–2139 (2009).
   PubMedGoogle Scholar
• Leffell MS, Zachary AA. The role of the histocompatibility laboratory in desensitization for transplantation. Curr. Opin. Organ. Transplant.14, 398–402 (2009).
   PubMedGoogle Scholar
• Reinsmoen NL, Lai CH, Vo A et al. Acceptable donor-specific antibody levels allowing for successful deceased and living donor kidney transplantation after desensitization therapy. Transplantation86(6), 820–825 (2008).
   PubMed Web of Science ®Google Scholar